Loading...
Powered By
12 items
2025-06-27
Mochida Pharmaceutical Co., Ltd. at its AGM held on June 27, 2025 approved changes of the Special Committee members under the Policy. Special Committee members after the changes as follows: Shigeaki Yoshikawa, Born in 1962; Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd.; Mar. 2015 Outside Director At Pilot Corporation May. 2015 Outside Director At Shochiku Co., Ltd. Mar. 2023; Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present) June 2023; Outside Director At Tv Asahi Holdings Corporation (To the Present); June 2025 Outside Director of the Company (To the Present). Yoshifumi Miyata; Born in 1952. Career Summary: Apr. 1978 Joined the Dai-Ichi Mutual Life Insurance Company; Apr. 2006 Executive Officer and General Manager of Financial Institution Relations Department At the Dai-Ichi Mutual Life Insurance Company; Apr. 2009 Managing Executive Officer of the Dai-Ichi Mutual Life Insurance Company Jun. 2010 Outside Audit & Supervisory Board Member of Tsugami Corporation; Jun. 2012 Representative Director and Vice-President of Trust & Custody Services Bank, Ltd.; Oct. 2018 Outside Director At Wellnest Communications Inc. (To the Present); Jun. 2021 Outside Audit & Supervisory Board Member of the Company (To the Present). Sanae Tanaka; Born in 1962. Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd; Mar. 2015 Outside Director At Pilot Corporation; May. 2015 Outside Director At Shochiku Co., Ltd.; Mar. 2023 Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present); Jun. 2023 Outside Director At Tv Asahi Holdings Corporation (To the Present) Jun. 2025 Outside Director of the Company (To the Present).
2025-06-17
Mochida Pharmaceutical Co., Ltd. at meeting of its Board of Directors held on May 12, 2025, announced board changes. The company announced Keiichi Sagisaka - Member of the Board, Senior Executive Managing Officer Pharmaceutical Business and Mochida Healthcare and Tomoo Kugisawa - Outside Director as Outgoing Directors. The company announced Changes of Representative Directors: Junichi Sakaki - Member of the Board, Senior Executive Managing Officer Supervisor for Business Development, Business Promotion and Biomaterials Business and Motoi Mitsuishi - Member of the Board, Senior Executive Managing Officer Planning & Administration, Head of Planning & Administration Division. Effective from June 27, 2025.
2025-06-04
Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 01, 2025
2025-05-28
Mochida Pharmaceutical Co., Ltd. expected to report Q1 2026 results on August 1, 2025. This event was calculated by S&P Global (Created on May 28, 2025).
2025-05-12
Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
2025-05-12
Mochida Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company expects net sales to be JPY 110,500 million. Operating profit to be JPY 7,000 million. Profit attributable to owners of parent to be JPY 5,400 million. Basic earnings per share to be JPY 152.33.
2025-05-12
Mochida Pharmaceutical Co., Ltd., Board Meeting, May 12, 2025. Agenda: To consider Change of Representative Directors and Directors.
2025-03-27
Mochida Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Mar-28-2025
2025-03-04
Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
2025-01-17
Mochida Pharmaceutical Co., Ltd. expected to report Fiscal Year 2025 results on May 13, 2025. This event was calculated by S&P Global (Created on January 17, 2025).
2024-11-30
Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025
2024-08-27
Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 01, 2024
2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | |
|---|---|---|---|---|---|---|---|---|
Total Revenues | 106,383 | 105,159 | 105,398 | 104,505 | 103,545 | 102,885 | 100,085 | 99,537 |
Pretax Income Excl.Unusual Items | 8,483 | 8,067 | 7,618 | 6,063 | 5,811 | 6,037 | 4,506 | 7,694 |
Total Assets | 161,743 | 160,121 | 166,050 | 158,434 | 158,051 | 158,800 | 157,825 | 156,400 |
Total Liabilities | 30,592 | 29,427 | 35,734 | 29,328 | 30,655 | 30,834 | 30,646 | 29,095 |
Cash & Cash Equivalents | 51,696 | 45,154 | 45,583 | 40,692 | 36,226 | 33,290 | 29,909 | 34,757 |
Total Common Equity | 131,151 | 130,694 | 130,316 | 129,106 | 127,396 | 127,966 | 127,179 | 127,305 |
Book Value Per Share (BVPS) | 3,699.56 | 3,686.66 | 3,675.94 | 3,641.81 | 3,593.56 | 3,609.61 | 3,579.89 | 3,573.78 |
Net Change in Cash | 23,860 | 15,033 | -13,720 | -14,846 | ||||
Capital Expenditure | -2,160 | -1,722 | -2,296 | -2,374 |
On August 01, 2025, Mochida Pharmaceutical shared its financial results for the second quarter of 2025, having revenues of 26.63B yen and net income of 1.89B yen, indicating a growth of 4.8% in revenue, in addition to a substantial 21.9% rise in EPS compared to the corresponding quarter of the previous year.
and it trades at 18.9x times current year's earnings, which is higher than the sector average (P/E 9.6x).